FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC)
Clinical trials for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC) explained in plain language.
Never miss a new study
Get alerted when new FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC) trials appear
Sign up with your email to follow new studies for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine targets rare liver cancer's genetic flaw
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage trial tests a personalized peptide vaccine for people with a rare liver cancer called fibrolamellar hepatocellular carcinoma (FLC) or other tumors that share a specific genetic change (DNAJB1-PRKACA fusion). The vaccine is designed to train the body's immune cell…
Matched conditions: FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC)
Phase: PHASE1 • Sponsor: University Hospital Tuebingen • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:04 UTC
-
New vaccine combo targets rare liver cancer in early trial
Disease control Recruiting nowThis early-phase trial tests a peptide vaccine designed to target a specific protein found in fibrolamellar carcinoma (FLC), a rare liver cancer. The vaccine is combined with two immunotherapy drugs (nivolumab and ipilimumab) to boost the immune system's attack on cancer cells. T…
Matched conditions: FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC)
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC